case_images: PMC9521673_01
case_images: Schematic representation of the patient's treatment history. IA, idarubicin and cytarabine; PR, partial remission; CR, complete remission; MST, micro-transplantation.
case_images: fimmu-13-1005364-g001.jpg
case_images: PMC9521673_01_fimmu-13-1005364-g001.jpg
case_images: f1
case_images: He then received one cycle of consolidation with the same regimen ( Figure 1 ).
case_images: Flowchart of the micro-transplantation protocol. BM, bone marrow; DAC, decitabine; G-CSF, granulocyte colony-stimulating factor; HAAG, homoharringtonine (HHT), cytarabine (Ara-C), aclarubicin (Acla), and G-CSF; MST, micro-transplantation.
case_images: fimmu-13-1005364-g002.jpg
case_images: PMC9521673_01_fimmu-13-1005364-g002.jpg
case_images: f2
case_images: No GVHD prophylactic was administered ( Figure 2 ).
case_images: (A) Changes in body temperature after the infusion; (B) Changes in alanine aminotransferase, aspartate aminotransferase, and total bilirubin after the infusion; (C) Changes in hematopoietic donor chimerism of the total PB cells (Left Panel) and sorted PB or BM cells (Right Panel) by polymerase chain reaction-based-short tandem repeats assay with a sensitivity of 1%; (D) Changes in PB cell count after the infusion. G-PBSCs, granulocyte colony-stimulating factor-mobilized peripheral blood stem cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; PB, peripheral blood; BM, bone marrow; WBC, white blood cell; HB, hemoglobin; PLT, platelet. PB and BM on the abscissa in (C) indicate the source of specimens for this examination.
case_images: fimmu-13-1005364-g003.jpg
case_images: PMC9521673_01_fimmu-13-1005364-g003.jpg
case_images: f3
case_images: Day 9 and persisted for approximately 2 weeks ( Figure 3B ). Donor chimerism in PB was 58.9% detected by polymerase chain reaction-based short tandem repeats (PCR-STR) on Day 9, which increased to complete donor chimerism (98.8%) by Day 18 ( Figure 3C ). On Day 12, PCR-STR of sorted PB cells revealed donor chimerism 87.62%, 63.24%, 66.44%, 96.73%, and 92.35% for CD34+stem cells, NK cells, T lymphocytes, Neutrophils, and B lymphocytes, respectively ( Figure 3C ), accompanied by mild rashes on the back, chest, palms. His neutrophils recovered on Day 18 while platelet engraftment was delayed ( Figure 3D ). PCR-pair end sequencing. PCR-STR of sorted BM cells revealed donor chimerism 98.16% and 86.34% for CD34+stem cells and T lymphocytes, respectively ( Figure 3C ).